ABOUT MEVION

Mevion has benefited from Dr. Lawrence Tian’s leadership as a member of the board of directors since 2015 and was appointed Chairman in 2018. Dr. Tian brings a wealth of experience from the life sciences and medical device industry to this role. He is a Founding Partner of YuanMing Capital, a leading private equity firm which focuses on the investment in pharmaceutical research and development, innovative medical devices and high-end medical services in both China and the United States. He also serves as the Chairman of Investment Committee of China Pharmaceutical Industry Research and Development Association, and he is a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong Limited.

Dr. Tian also brings experience networking business leaders to the Mevion leadership team. He is the founder and Chairman of the China Entrepreneurs Forum, the most influential business owners association in China, and is the founder of the China-U.S. Business Leaders Roundtable, a prestigious cross-border communication platform.

Prior to Mevion, Dr. Tian has had successful career as a serial entrepreneur with a strong track record of success. In the financial markets, he founded China International Futures Co., Ltd. (CIFCO) in 1992. CIFCO grew into a leading brokerage firm and achieved the largest market share in China during his chairmanship. He also co-founded Wumart Group in 1994, which is currently the largest supermarket chain in Northern China.

Dr. Tian obtained his master’s degree and doctoral degree from Wuhan University. He received the China Economics Theory Innovation Award, China’s highest prize for economics. 

Dr. Tina Tianning Yu is the Chief Executive Officer and President of Mevion Medical Systems, the leader in compact proton therapy. With over 20 years of experience in life sciences, healthcare, and finance, Dr. Yu brings a unique blend of scientific expertise and business acumen to advancing cancer care.

Prior to Mevion, she was a Co-Founding Partner of YuanMing Capital, leading investments in successful biotech companies, including BeiGene and Ascentage Pharmaceuticals. Her career includes financial experience at institutions such as Vision Capital, Fidelity Asia Ventures, Morgan Stanley and Genzyme Biopharma, as well as scientific positions at Wyeth BioPharma.

Under Dr. Yu’s leadership, Mevion has achieved significant global growth and strong financial performance, becoming the preferred proton therapy provider for more NCI-Designated Comprehensive Cancer Centers. She led the development of the groundbreaking MEVION S250-FIT*, the first proton therapy system designed for existing LINAC vaults. This system significantly reduces proton therapy’s size and complexity, enabling any health systems to bring proton therapy and benefit more patients.

Dr. Yu is a member of the CEOs Against Cancer - New England Chapter and was named to the Worcester Business Journal’s “Power 50” list. She is also a Regional Director with the Harvard Business School Healthcare Alumni Association. She holds a Ph.D. in Chemistry from Princeton, an MBA from Harvard, and a B.S. in Biology from the University of Science
and Technology of China.

*The MEVION S250-FIT Proton Therapy System is not yet available for clinical use.

Curt Kienast has been a pivotal leader at Mevion since 2007, driving its evolution into the global leader in compact proton therapy. With a background in the defense and healthcare industries, Curt joined Mevion as Director of Software Quality, advancing through key leadership roles in quality, engineering, service, and manufacturing. His strategic vision and operational expertise have been instrumental in streamlining manufacturing processes and delivering cutting-edge solutions. As Chief Operating Officer, Curt oversees Mevion’s operations, ensuring excellence in innovation, delivery, and service. He holds a Bachelor of Science in Computer Engineering from Embry-Riddle Aeronautical University.